Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease
Inflammation is a major component in the pathology of chronic lung diseases, including asthma. Anti-inflammatory treatment with corticosteroids is not effective in all patients. Thus, new therapeutic options are required to control diverse cellular functions that are currently not optimally targ...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2007-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2007/14983 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849304542433247232 |
|---|---|
| author | Jane Elizabeth Ward Xiahui Tan |
| author_facet | Jane Elizabeth Ward Xiahui Tan |
| author_sort | Jane Elizabeth Ward |
| collection | DOAJ |
| description | Inflammation is a major component in the pathology of chronic lung diseases, including asthma.
Anti-inflammatory treatment with corticosteroids is not effective in all patients. Thus, new therapeutic
options are required to control diverse cellular functions that are currently not optimally targeted by
these drugs in order to inhibit inflammation and its sequelae in lung disease. Peroxisome proliferator
activated receptors (PPARs), originally characterised as regulators of lipid and glucose metabolism,
offer marked potential in this respect. PPARs are expressed in both lung infiltrating and resident
immune and inflammatory cells, as well as in resident and structural cells in the lungs, and play
critical roles in the regulation of airway inflammation. In vitro, endogenous and synthetic ligands for
PPARs regulate expression and release of proinflammatory cytokines and chemoattractants,
and cell proliferation and survival. In murine models of allergen-induced inflammation, PPARα and PPARγ ligands reduce the influx of inflammatory cells, cytokine and mucus production, collagen deposition, and airways hyperresponsiveness. The activity profiles of PPAR ligands differ to
corticosteroids, supporting the hypothesis that PPARs comprise additional therapeutic targets to
mimimise the contribution of inflammation to airway remodelling and dysfunction. |
| format | Article |
| id | doaj-art-3bdba4c1d71e4226b32a0e0d68a6fd37 |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2007-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-3bdba4c1d71e4226b32a0e0d68a6fd372025-08-20T03:55:41ZengWileyPPAR Research1687-47571687-47652007-01-01200710.1155/2007/1498314983Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung DiseaseJane Elizabeth Ward0Xiahui Tan1Department of Pharmacology, University of Melbourne, Victoria 3010, AustraliaDepartment of Pharmacology, University of Melbourne, Victoria 3010, AustraliaInflammation is a major component in the pathology of chronic lung diseases, including asthma. Anti-inflammatory treatment with corticosteroids is not effective in all patients. Thus, new therapeutic options are required to control diverse cellular functions that are currently not optimally targeted by these drugs in order to inhibit inflammation and its sequelae in lung disease. Peroxisome proliferator activated receptors (PPARs), originally characterised as regulators of lipid and glucose metabolism, offer marked potential in this respect. PPARs are expressed in both lung infiltrating and resident immune and inflammatory cells, as well as in resident and structural cells in the lungs, and play critical roles in the regulation of airway inflammation. In vitro, endogenous and synthetic ligands for PPARs regulate expression and release of proinflammatory cytokines and chemoattractants, and cell proliferation and survival. In murine models of allergen-induced inflammation, PPARα and PPARγ ligands reduce the influx of inflammatory cells, cytokine and mucus production, collagen deposition, and airways hyperresponsiveness. The activity profiles of PPAR ligands differ to corticosteroids, supporting the hypothesis that PPARs comprise additional therapeutic targets to mimimise the contribution of inflammation to airway remodelling and dysfunction.http://dx.doi.org/10.1155/2007/14983 |
| spellingShingle | Jane Elizabeth Ward Xiahui Tan Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease PPAR Research |
| title | Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease |
| title_full | Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease |
| title_fullStr | Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease |
| title_full_unstemmed | Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease |
| title_short | Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease |
| title_sort | peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease |
| url | http://dx.doi.org/10.1155/2007/14983 |
| work_keys_str_mv | AT janeelizabethward peroxisomeproliferatoractivatedreceptorligandsasregulatorsofairwayinflammationandremodellinginchroniclungdisease AT xiahuitan peroxisomeproliferatoractivatedreceptorligandsasregulatorsofairwayinflammationandremodellinginchroniclungdisease |